ProMIS Neurosciences, Inc. (TSE:PMN – Get Free Report) dropped 3.8% during trading on Monday . The company traded as low as C$5.98 and last traded at C$6.00. Approximately 19,701 shares were traded during mid-day trading, an increase of 492% from the average daily volume of 3,327 shares. The stock had previously closed at C$6.24.
ProMIS Neurosciences Stock Performance
The company’s 50-day moving average is C$6.00. The company has a quick ratio of 1.30, a current ratio of 0.51 and a debt-to-equity ratio of 108.33. The stock has a market cap of C$51.48 million, a P/E ratio of -1.78 and a beta of 1.19.
About ProMIS Neurosciences
ProMIS Neurosciences, Inc discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.
See Also
- Five stocks we like better than ProMIS Neurosciences
- 3 Warren Buffett Stocks to Buy Now
- Goldilocks CPI Report Leads Market to Sell Off, Lower Lows Ahead
- What Are Dividend Champions? How to Invest in the Champions
- GameStop: Earnings Won’t Save It, Dilution Points to Trouble
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Dividend Aristocrats or Dividend Kings: Which Is Best for You?
Receive News & Ratings for ProMIS Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMIS Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
